Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Flucelvax in Healthy Adults
NCT02256488Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) in influenza, sponsored by Novartis. Started Sep 2014; status: completed.
02
Drugs
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02256488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256488.